Why the study?
Does spironolactone improve outcomes in patients with heart failure with a preserved ejection fraction?
Does spironolactone improve outcomes in patients with heart failure with a preserved ejection fraction?
No takes yet. Share an insight, caveat, or question.
This editorial discusses the TOPCAT trial evaluating spironolactone versus placebo in patients with heart failure with preserved ejection fraction.
McMurray et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: